Finilac

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Finilac

Property Description
Active ingredient Cabergoline (INN)
Form Oral Solution
Pharmacological class Prolactin Inhibitor / Dopamine Receptor Agonist
General Purpose To achieve hormonal balance by lowering prolactin levels
Origin Synthetic Ergoline Derivative

What Type of Medicine is Finilac? (Definition and Classification)

Finilac is a prescription-only medicinal preparation whose sole active ingredient is Cabergoline (INN), a compound classified fundamentally as a potent Prolactin Inhibitor. Chemically, Cabergoline is designated as a synthetic ergoline derivative and operates within the pharmacological class of Dopamine Receptor Agonists. This classification signifies that the substance mimics the function of the body's natural dopamine, targeting specific D2 receptors to regulate hormonal release. Pharmacological data indicates that Cabergoline is recognized for its high selectivity and extended duration of action on the dopamine receptor, making it a reliable agent for sustained hormonal control.

Finilac's Composition and Physical Form

Finilac is supplied as an oral solution, a clear liquid formulation intended for the oral route of administration. This form is a key factor, as the active ingredient is often available in tablet forms under different brands. Finilac is a single active ingredient product, with the therapeutic effect resting entirely on Cabergoline. The composition consists of the active substance dissolved in a non-aqueous base of medium-chain triglycerides. The liquid presentation ensures the ability to deliver accurate and precise quantities of the potent active substance, a crucial feature when managing precise hormonal levels.

What is the General Purpose of This Medicine? (High-Level Function)

The primary purpose of Finilac is to achieve hormonal balance by specifically creating an inhibitory effect on prolactin secretion. The medicine functions by directly stimulating dopamine receptors in the pituitary gland, sending a signal to significantly reduce the body's output of the prolactin hormone. This action makes Finilac an effective prolactin-lowering agent, typically applied when a patient needs reliable and sustained control over excessive prolactin production.

What side effects are possible with Finilac?

Finilac’s safety profile, documented in official prescribing information, classifies adverse reactions by frequency and the body system affected, strictly following regulatory standards.

Frequency-Classified Adverse Reactions

Adverse events are often concentrated in the Gastrointestinal and Nervous System categories:

  • Very Common (ge 10%): Headache, Dizziness, Nausea, Abdominal pain, and Fatigue.
  • Common (ge 1% to <10%): Constipation, Vomiting, Somnolence, Depression, and Postural Hypotension (dizziness upon standing).
  • Uncommon (ge 0.1% to <1%): Pleural effusion and Pulmonary fibrosis.

Serious Safety Considerations and Regulatory Warnings

Official labels highlight the potential for serious, less frequent adverse reactions, primarily associated with long-term exposure. These include Cardiac Valvulopathy (valvular heart disease) and various forms of Fibrotic Disorders, such as Pleural, Pulmonary, and Retroperitoneal Fibrosis. These conditions are explicitly linked to long-term administration of the active substance.

Safety information also includes specific warnings regarding use for lactation inhibition in postpartum women, where serious cardiovascular and neurological events, including stroke and myocardial infarction, have been reported. Postural Hypotension is officially noted as more common at the start of treatment, while the medicine is generally restricted (contraindicated) in individuals with uncontrolled hypertension or a documented history of fibrotic disorders. Patients should be monitored for the development of Impulse Control Disorders.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes a Finilac overdose as being associated with effects on the gastrointestinal, cardiovascular, and central nervous systems.

Documented Overdose Presentations

Symptoms reported in cases of overexposure, particularly a single overdose, include vomiting and hypotension (low blood pressure). The most serious neurological symptoms reported have included convulsions. Less specific, but documented, signs may include stuffy nose, fainting, or hallucinations (seeing or hearing things that are not present).

Required Emergency Action

In the event of overdosage, general supportive measures should be undertaken. This includes steps to remove any unabsorbed drug from the system and, if necessary, to maintain blood pressure. The official management approach also notes that the use of dopamine antagonist drugs, such as metoclopramide, may be considered as a specific management strategy.

When Immediate Medical Help is Required

Immediate medical attention is required in the event of any suspected overdose. This is explicitly mandated in cases of accidental ingestion, particularly if the ingestion involves a child. You should seek emergency medical services at once if the victim has collapsed, has a seizure, or has trouble breathing. If possible, show the physician the product label or package leaflet.

Therapeutic Uses of Finilac

What Finilac Treats: Main Uses and Benefits

Finilac is applied in clinical settings that involve acute or unstable symptom patterns, where symptomatic relief is needed in the key domains of reproduction and lactation. It helps address groups of symptoms that may appear suddenly and create noticeable interference with an animal's comfort and daily stability.

The therapeutic areas for Finilac are relevant for the supportive management of symptoms related to false pregnancy in bitches and the temporary management of lactation in bitches and queens. The medication is commonly used to help manage challenging physical and emotional signs associated with false pregnancy, and it is considered relevant in situations requiring short-term supportive relief to help manage the production of milk.

“This supportive action helps ease the overall symptom burden during periods of heightened discomfort.”

Easing Symptoms of False Pregnancy (Pseudopregnancy)

This medication is commonly used to help manage the challenging physical and emotional signs associated with false pregnancy. It is applied in addressing pronounced symptoms such as the swelling of mammary glands, unwanted milk production, and disruptive behavioral changes like nesting. Finilac, when used in these acute symptomatic episodes, may support a sense of stability and may assist with maintaining functional stability.

Supporting Management of Unwanted or Excess Lactation

Finilac is considered relevant in situations requiring short-term supportive relief to help manage the production of milk. This use may be applicable when lactation is no longer needed—for example, following the loss of offspring or early weaning—or when excess milk accumulation is causing discomfort and congestion (galactostasis). The main therapeutic benefit provides supportive relief that may assist in easing unwanted milk secretion and supports general well-being during symptomatic phases.

Quick Fact: Relief for Mammary Swelling and Distress

Regulatory References

  1. UK Veterinary Medicines Directorate Summary of Product Characteristics

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Finilac — Official Regulatory Information

Eligibility Scope

Classification Eligible Populations
Allowed Bitches (Dogs) and Queens (Cats)
Contraindicated Pregnant Animals (risk of abortion); Animals with known hypersensitivity to Cabergoline or excipients.
Conditional Use Lactating animals (permitted only when suppression of lactation is required).
Caution Recommended Animals with significantly impaired liver function.

Populations for whom use is contraindicated (Absolute Prohibition):

  • Animals concurrently treated with hypotensive drugs or dopamine antagonists (due to risk of reduced efficacy or transient hypotension).
  • Animals directly after surgery while under the influence of anaesthetic agents.

Age-related eligibility rules:

  • No specific restrictions regarding minimum age or older-adult use are formally defined in the official contraindication sections.

Eligibility Classifications (High-Level)

Eligibility severity classification (as defined in official documents):

  • Contraindicated: Absolute prohibition (e.g., Pregnant Animals).
  • Caution is recommended: Limitation on use requiring special consideration (e.g., Significant Liver Impairment).

Connection to the overall eligibility profile: Official regulatory documents define who can and cannot use this medicine by establishing multiple layers of absolute prohibition and conditional caution. Contraindications prohibit use based on reproductive status, concurrent drug therapies, and immediate post-surgical state. Eligibility remains conditional based on specific organ function status, which serves as the formal regulatory framework for appropriate population use.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation identifies two primary classes of medicinal products that are contraindicated for concurrent use with Finilac (cabergoline) due to pharmacodynamic interactions.

Documented Pharmacodynamic and Procedural Constraints

Classification Interacting Product Category Practical Regulatory Restriction
Contraindicated Dopamine Antagonists (e.g., Phenothiazines, Metoclopramide) Must not be co-administered; the interaction may reduce or negate the therapeutic effect.
Contraindicated Hypotensive Drugs Must not be co-administered due to the potential for Finilac to induce transient hypotension, which creates an additive risk of reduced blood pressure.
Timing-Based Anaesthetic Agents Do not use directly after surgical procedures while the subject is still under the influence of these agents.
Physical Incompatibility Other Aqueous Solutions (e.g., Milk) The oral solution must not be mixed with other aqueous solutions or other veterinary medicinal products in the absence of compatibility studies.

General Interaction Context

The interaction profile is predominantly structured around pharmacodynamic antagonism and additive effects, explicitly listing combinations to avoid to prevent loss of efficacy or compounding the risk of hypotension. Furthermore, caution is recommended when the product is used in subjects with significantly impaired liver function, which is a condition that may affect the overall handling of the medication.

Mechanism of Action

Receptor-Mediated Signaling Modulation

Finilac acts within domains involving receptor- or enzyme-mediated signaling by initiating or suppressing specific signaling sequences. This modification of early molecular steps in the cascade contributes to limiting activity within overactive physiological pathways by influencing the concentration or downstream effects of mediators.


Modulation of Dysregulated Processes

The compound influences biochemical mechanisms involved in overactive or dysregulated cell processes within affected biological systems. It modulates signaling patterns to promote pathway equilibrium, resulting in measurable physiological changes within targeted systems.


Targeted Pathway Adjustment

Finilac is relevant in systems where targeted pathway adjustment is required to alter activity that may escalate under certain conditions. It modifies key pathways associated with heightened physiological responses by influencing feedback regulation within pathways where multiple layers of pathway activation occur.

Dosage and Administration Information

How Finilac is Used

The administration of Finilac (Cabergoline oral solution) follows a precise, weight-dependent protocol. This approach ensures delivery of the active substance via the approved route for the specified duration, without crossing into therapeutic claims or safety guidance. The usage pattern is defined by frequency, duration, and administration context.


Usage Parameter Administration Rule
Route of Administration The approved method of use is oral use only.
Dosing Regimen The dose is calculated as 0.1 ml per 1 kg body weight, which is equivalent to 5 microgram of Cabergoline per 1 kg of body weight.
Frequency and Duration Administered once daily for a treatment course lasting 4 to 6 consecutive days. The course may be repeated if signs recur.
Administration Condition The solution may be given directly into the mouth or can be administered by mixing with a small amount of food.

The procedural structure for using this oral solution is a once-daily schedule for a fixed duration. The protocol emphasizes that accurate body weight determination is required to ensure the correct dose calculation prior to starting treatment. Furthermore, the protocol excludes mixing the oral solution with aqueous solutions, such as milk.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Finilac


Evidence for Use in Managing False Pregnancy Symptoms

Research examined studies exploring how symptoms change over time in bitches experiencing false pregnancy (pseudopregnancy), a condition presenting with cycles of stability and flare-ups. The research included controlled clinical studies, sometimes comparing the use of the medicine against supportive care alone. Studies primarily focused on outcomes related to physical discomfort and outcomes reflecting daily functioning.

Research describes patterns related to how symptom measurements shifted in the observed populations over the defined study intervals. This involved monitoring the resolution of physical signs such as the swelling of mammary glands, and behavioral changes such as nesting or restlessness. The findings report the specific measurements observed in the studies over the short treatment period. These results apply only to the populations studied and were measured during periods of increased symptom activity.


Evidence for Use in Suppressing Unwanted Lactation

Studies explored the research base for the cessation of unwanted milk production by observing responses over defined time intervals. Research focused on cases where lactation was no longer required, such as following the loss of offspring. The studies explored measurements of milk secretion cessation and the regression of the mammary glands in both bitches (dogs) and queens (cats). This research provides insight into short-term changes and patterns observed during the initial treatment course.

In these research scenarios, findings indicate patterns related to the time it took for milk production to stop completely and for the regression of the glands to their normal size. Studies monitored these physiological changes during the acute phase where symptoms may vary in intensity. The evidence contributes to understanding symptom patterns when a temporary physiological imbalance is being examined.


What is Still Uncertain in the Research Record

What remains unclear is the long-term duration of the reported measurements and the patterns of recurrence after the medicine was evaluated in this research setting. There is limited information for long-term outcomes regarding the possible recurrence of false pregnancy episodes. Furthermore, the evidence quality varies across studies, as some pivotal research was non-randomized or non-blinded.

Research for queens (cats) is less comprehensive than for dogs. This means that for some groups, the subgroup findings are uncertain or less well-established, and the data for certain groups remain insufficient to draw broad conclusions across all target species.

Key Studies & References UK Veterinary Medicines Directorate Summary of Product Characteristics (SPC) for Cabergoline Oral Solution

Frequently Asked Questions (FAQ)

Common questions about Finilac (FAQ)


Q: How quickly does Finilac start working for most people?

Studies on the active substance indicate that the maximum effect of inhibiting prolactin (the hormone Finilac targets) is reported to be achieved within 4 to 8 hours following administration. Following this initial peak, the effect is described in official product information as lasting several days, with the duration depending on the specific amount administered.


Q: What happens if I stop taking Finilac suddenly?

The treatment is structured as a short course lasting 4 to 6 consecutive days. Official regulatory instructions state that if the signs of the condition fail to resolve or recur after the end of the initial treatment, the course may be repeated. The protocol does not include a requirement for gradual withdrawal.


Q: Is Finilac considered a long-term treatment option?

The product is officially administered as a short course of treatment, typically lasting only 4 to 6 consecutive days. Regulatory warnings on rare, serious adverse effects like fibrotic disorders (scarring of tissues) are generally associated with the long-term exposure of the active substance in certain regulatory contexts.


Q: Can Finilac affect mood or concentration?

Official safety data lists somnolence (drowsiness) as a reported adverse event, which can affect concentration. Other common adverse reactions found in regulatory documents include depression. These effects are linked to the nervous system and are documented in safety information.


Q: Are there any specific foods or drinks to avoid while using Finilac?

The solution is approved to be mixed with food or given directly into the mouth. However, official regulatory documents indicate that the solution must not be mixed with other aqueous solutions, such as water or milk, due to physical incompatibility.


Q: Is it normal to feel tired or dizzy when first starting Finilac?

Both drowsiness and fatigue are listed as very common adverse events in official safety data. Dizziness and low blood pressure (hypotension) are also reported side effects, and some of these feelings are noted as being transient (short-lived) or more likely to occur after the very first dose is administered.


Q: How is Finilac different from other similar medicines?

Finilac is characterized by its specific pharmacological classification. Its active ingredient is a synthetic ergoline derivative that operates as a potent Dopamine Receptor Agonist. Its mechanism of action involves targeting specific receptors to achieve its primary purpose of inhibiting prolactin secretion.


Q: What is the maximum duration a person can be on Finilac?

The standard duration for a single course of treatment is specified in official instructions as a fixed period of 4 to 6 consecutive days. Official instructions indicate the course can be repeated if signs recur.


Q: Does Finilac cause weight gain or weight loss?

Official adverse event reporting for the target species includes anorexia (loss of appetite) as a rare event. Safety data for the active substance indicates that both weight loss and weight gain have been reported as adverse effects in other regulatory contexts.


Q: Are the side effects of Finilac permanent?

Most common adverse events, such as vomiting and drowsiness, are generally described as transient (short-lived) in nature. However, official safety documentation notes that rare, serious effects like fibrotic disorders are primarily associated with the long-term exposure of the active substance in certain regulatory settings.


Q: What is the difference between Finilac and a generic version?

Finilac is the brand name of the medicine. The sole active ingredient it contains is Cabergoline. A generic product would contain the identical active ingredient and be manufactured to meet the same strict regulatory standards, but would be sold under the chemical name or a different brand name.


Q: Is Finilac safe to use while pregnant or breastfeeding?

Official regulatory documents indicate the medicine is not suitable for use during pregnancy because it carries the capacity to cause abortion. It should not be used in lactating animals unless the specific purpose of the treatment is to achieve the suppression of lactation.


Q: Does Finilac affect fertility in men or women?

Finilac is not indicated for the promotion of fertility. Its mechanism of action is to inhibit prolactin secretion, a hormone that plays a key role in reproductive cycles. Its use is contraindicated in pregnant animals.


Q: Are there long-term risks associated with using Finilac?

Official safety data for the active substance indicates potential for serious, less common adverse reactions like Cardiac Valvulopathy (heart valve disease) and various Fibrotic Disorders (scarring of tissues) explicitly linked to long-term exposure. The veterinary product is, however, intended for short-term courses.


Q: Can Finilac be taken on an empty stomach?

The official administration instructions confirm that the product is approved to be administered either directly into the mouth or by mixing with a small amount of food. The instructions indicate that its use is not dependent on being taken exclusively with a full meal.


Q: What are the signs of an allergic reaction to Finilac?

Allergic reactions are reported as very rare in the official product information. Signs of a reaction have included skin-related symptoms such as pruritus (itching), urticaria (hives), dermatitis, and oedema (swelling).


Q: Is Finilac suitable for children or teenagers?

Finilac is authorized only as a veterinary medicinal product for use in specific animal populations, namely Bitches (Dogs) and Queens (Cats).


Q: How long does it take for Finilac to be completely out of my system?

Pharmacokinetic studies have examined the active substance and reported that the plasma elimination half-life in the target species ranges approximately from 10 to 19 hours. This figure describes the time required for the amount of substance in the body to be reduced by half.


Q: What kind of studies support the use of Finilac?

The use of the medicine is supported by controlled clinical studies that specifically examined changes in symptom measurements over time in target animal populations experiencing either false pregnancy (pseudopregnancy) or unwanted lactation.


Q: Is it true that Finilac can cause changes in sleep patterns?

Yes. Somnolence (drowsiness) is listed as a known adverse event. Safety information for the active substance in other regulatory contexts also mentions other sleep pattern disturbances, including insomnia.


Q: Does Finilac have any potential for misuse?

Regulatory safety information for the active substance in human contexts includes warnings concerning the potential development of Impulse Control Disorders (e.g., pathological gambling or hypersexuality). This is considered a specific behavioral risk documented in the safety information.


Q: What is the experience of people who have been on Finilac for a long time?

Official research and evidence summaries acknowledge that there is limited information available for long-term outcomes regarding the recurrence of conditions after the medicine was evaluated in the short-term research setting. The focus of the product is on short-term use.


Q: What if I take two doses of Finilac by mistake?

Regulatory data on a single overdose indicates a potential for an increased likelihood of experiencing vomiting and possibly an increase in transient hypotension (a short-lived drop in blood pressure).


Q: Is Finilac effective for every person who takes it?

Official research findings for the medicine are described as applying only to the populations studied during clinical trials. As with any medication, the effectiveness can vary between individuals based on their unique physiological response.


Q: Can stress or illness affect how Finilac works?

The product information recommends that caution should be exercised in target animals that have significantly impaired liver function. This condition is noted because it may affect the medicine's overall processing by the body.


Q: How long does the effect of a single dose of Finilac last?

The maximum inhibitory effect on prolactin secretion following a single dose is described in regulatory documents as lasting for several days, with the exact duration dependent on the specific amount that was administered.


Q: Do I need to change my diet while taking Finilac?

For the indication of false pregnancy, official documents state that additional supportive treatments may be advised. These supplementary recommendations may involve restrictions on water and carbohydrate intake, along with increased exercise.


Q: Can older adults use Finilac safely?

The official regulatory contraindication sections do not define specific restrictions regarding use in older-aged target animals. Caution is officially advised only in cases where the animal has significantly impaired liver function.

How should Finilac be stored and disposed of?

How to Store and Dispose of Finilac?

The storage and disposal of Finilac 50 microgram/ml oral solution must strictly follow the official regulatory requirements to ensure product stability and safety.

Storage Requirements

Finilac must not be stored above 30 °C. To maintain stability, the product must be kept in the outer carton in order to protect from light. The labeled shelf life of the oral solution after the bottle is first opened is 28 days.

Handling and Safety

In accordance with mandatory regulatory statements, this medicine must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Finilac must not be disposed of via wastewater or household waste. Disposal must instead be carried out through authorized pharmaceutical take-back schemes or national collection systems, which are required to protect the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Finilac found in:

A-Z Index: